Literature DB >> 7668124

The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1.

P H Aguiar1, M Tatagiba, M Samii, E Dankoweit-Timpe, H Ostertag.   

Abstract

Formalin-fixed paraffin sections of 55 consecutive bilateral vestibular schwannomas in 46 patients with neurofibromatosis 2 (NF2), and 50 patients with unilateral vestibular schwannomas were investigated immunohistochemically with the monoclonal antibody MIB 1 directed against recombinant parts of Ki-67 antigen. The immunohistochemical staining was carried out on dewaxed microwave oven-processed paraffin sections of formalin-fixed tumour tissues. The labelling index (LI) obtained was compared to clinical and histological findings in both groups. There was no correlation between the LI and age of the patients, tumour size, or histological type of tumour (Antoni A or B). Vestibular schwannomas in NF2 showed higher LI than unilateral vestibular schwannomas: the maximal LI found per section (LI max) ranged from 0.4 to 17.6% (mean, 2.7%) in NF2 schwannomas, and from 0 to 9% (mean, 2.2%) in unilateral schwannomas. These differences may express immunohistochemically some clinical and morphological differences between bilateral and unilateral vestibular schwannomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7668124     DOI: 10.1007/bf01428500

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  16 in total

1.  Clinical growth rate of acoustic schwannomas: correlation with the growth fraction as defined by the monoclonal antibody ki-67.

Authors:  T H Lesser; R C Janzer; P Kleihues; U Fisch
Journal:  Skull Base Surg       Date:  1991

2.  The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology.

Authors:  P C Burger; T Shibata; P Kleihues
Journal:  Am J Surg Pathol       Date:  1986-09       Impact factor: 6.394

3.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

4.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

5.  S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.

Authors:  T Hoshino; T Nagashima; K G Cho; J A Murovic; J E Hodes; C B Wilson; M S Edwards; L H Pitts
Journal:  Int J Cancer       Date:  1986-09-15       Impact factor: 7.396

6.  Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors.

Authors:  G Reifenberger; M Deckert; W Wechsler
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

7.  Acoustic neurinoma in the elderly: factors predictive of postoperative outcome.

Authors:  M Samii; M Tatagiba; C Matthies
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

Review 8.  Neurofibromatosis and central nervous system tumors in childhood.

Authors:  T B Mapstone
Journal:  Neurosurg Clin N Am       Date:  1992-10       Impact factor: 2.509

9.  Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases.

Authors:  R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1993-03       Impact factor: 3.685

10.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

View more
  7 in total

1.  Microsurgical Management of Trigeminal Schwannoma: Cohort Analysis and Systematic Review.

Authors:  Maick Willen Fernandes Neves; Paulo Henrique Pires de Aguiar; Telmo Augusto Barba Belsuzarri; André Monteiro Soares de Araujo; Samantha Lorena Paganelli; Marcos Vinicius Calfat Maldaun
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-28

2.  A Unified Methodological Framework for Vestibular Schwannoma Research.

Authors:  Lukas D Landegger; Jessica E Sagers; Sonam Dilwali; Takeshi Fujita; Mehmet I Sahin; Konstantina M Stankovic
Journal:  J Vis Exp       Date:  2017-06-20       Impact factor: 1.355

3.  BDNF mRNA expression is significantly upregulated in vestibular schwannomas and correlates with proliferative activity.

Authors:  Frauke Kramer; Timo Stöver; Athanasia Warnecke; Marc Diensthuber; Thomas Lenarz; Kirsten Wissel
Journal:  J Neurooncol       Date:  2009-11-25       Impact factor: 4.130

4.  Proliferation rate of intracranial meningiomas as defined by the monoclonal antibody MIB-1: correlation with peritumoural oedema and other clinicoradiological and histological characteristics.

Authors:  Paulo Henrique Aguiar; Ana Maria Tsanaclis; Oswaldo Inácio Tella; José Pindaro Plese
Journal:  Neurosurg Rev       Date:  2003-04-08       Impact factor: 3.042

5.  The fate of spinal schwannomas following subtotal resection: a retrospective multicenter study by the Korea spinal oncology research group.

Authors:  Seil Sohn; Chun Kee Chung; Sung-Hye Park; Eun-Sang Kim; Ki-Jeong Kim; Chi Heon Kim
Journal:  J Neurooncol       Date:  2013-06-30       Impact factor: 4.130

6.  Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2.

Authors:  Eiji Ito; Kiyoshi Saito; Hiroshi Yatsuya; Tetsuya Nagatani; Goro Otsuka
Journal:  Neurosurg Rev       Date:  2009-08-12       Impact factor: 3.042

7.  [18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.

Authors:  Jose M Anton-Rodriguez; Daniel Lewis; Ibrahim Djoukhadar; David Russell; Peter Julyan; David Coope; Andrew T King; Simon K L Lloyd; D Gareth Evans; Alan Jackson; Julian C Matthews
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.